Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8041928 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP2C9AKR1C3RECQLAKR1C1 | |
| SCHEMBL781849 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP2C9AKR1C3RECQLAKR1C1 | |
| SCHEMBL8865069 | 0.89 | TP53 (0.59) | CYP3A4CYP2C9AKR1C3RECQLAKR1C1 | |
| SCHEMBL8865055 | 0.89 | TP53 (0.59) | CYP3A4CYP2C9AKR1C3RECQLAKR1C1 | |
| SCHEMBL8864851 | 0.84 | CYP3A4 (0.47) | CYP3A4CYP2C9AKR1C3HTTMEN1 | |
| SCHEMBL8864844 | 0.84 | CYP3A4 (0.47) | CYP3A4CYP2C9AKR1C3HTTMEN1 | |
| SCHEMBL2347233 | 0.84 | CYP3A4 (0.50) | CYP3A4CYP2C9AKR1C3RECQLAKR1C1 | |
| SCHEMBL8575022 | 0.84 | CYP3A4 (0.59) | CYP3A4CYP2C9AKR1C3RECQLAKR1C1 | |
| SCHEMBL7826083 | 0.84 | CYP3A4 (0.47) | CYP3A4CYP2C9AKR1C3RECQLAKR1C1 | |
| SCHEMBL7826086 | 0.84 | CYP3A4 (0.47) | CYP3A4CYP2C9AKR1C3RECQLAKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113999154-B | Compound and preparation method and application thereof | 国药东风总医院 | 2023-03-21 | — | — | CN | claimed |
| CN-113999154-A | Compound and preparation method and application thereof | 国药东风总医院 | 2022-02-01 | — | — | CN | claimed |
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| CN-113999154-B | Compound and preparation method and application thereof | 国药东风总医院 | 2023-03-21 | — | — | CN | disclosed |
| CN-113999154-B | Compound and preparation method and application thereof | 国药东风总医院 | 2023-03-21 | — | — | CN | disclosed |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| CN-113999154-A | Compound and preparation method and application thereof | 国药东风总医院 | 2022-02-01 | — | — | CN | disclosed |
| CN-113999154-A | Compound and preparation method and application thereof | 国药东风总医院 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020102100-A9 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-01-06 | — | — | WO | disclosed |
| EP-3880666-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113166081-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-7585997-B2 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTERPRISES LIMITED (KY) | 2009-09-08 | — | — | US | disclosed |
| EP-1709155-A4 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1709155-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | Kashfi, Khosrow (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CONVERSANT INTELLECTUAL PROPERTY MANAGEMENT INC. (CA) | 2005-08-18 | — | — | US | disclosed |
| WO-2005065361-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1000024-A1 | MERCAPTOACYLAMINO ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006365-A1 | MERCAPTOACYLAMINO ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1999-02-11 | — | — | WO | disclosed |
| US-5646313-A | PREPARING ENKEPHALINASE INHIBITORS | SOCIETE CIVILE BIOPROJET (FR) | 1997-07-08 | — | — | US | disclosed |
| US-5612371-A | ENZYME INHIBITORS | SOCIETE CIVILE BIOPROJECT (FR) | 1997-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CYP3A4 2521/4885CYP2C9 3399/4885AKR1C3 1506/4885 |
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | PYGL, TP53, MKI67 | CYP3A4 3652/4885CYP2C9 4349/4885AKR1C3 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.